Cohort Study of Osimertinib Combined with Pemetrexed and Carboplatin as First-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients with Poor Prognosis EGFR Mutations

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 86f8a9bf9219ec43627835a7a42adefb313b4a98
First added on: Oct 10, 2026